Cerebral amyloidosis associated with cognitive decline in autosomal dominant Alzheimer disease

Neurology

Volumn 85, Issue 9, 2015, Pages 790-798

  Wang, Fen ^a   Gordon, Brian A ^a   Ryman, Davis C ^a   Ma, Shengmei ^a,m   Xiong, Chengjie ^b   Hassenstab, Jason ^a,l   Goate, Alison ^a   Fagan, Anne M ^a,j   Cairns, Nigel J ^a,k   Marcus, Daniel S ^g   McDade, Eric ^a,n   Ringman, John M ^a,o   Graff Radford, Neill R ^a,p   Ghetti, Bernardino ^a   Farlow, Martin R ^c   Sperling, Reisa ^d   Salloway, Steve ^e   Schofield, Peter R ^f   Masters, Colin L ^h   Martins, Ralph N ^g   Rossor, Martin N ^a   Jucker, Mathias ^a   Danek, Adrian ^a   Förster, Stefan ^a   Lane, Christopher A S ^h   Morris, John C ⁱ   Benzinger, Tammie L S ^a   Bateman, Randall J ^a   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MAYO CLINIC   (United States)

^e Department of Pathology and Laboratory Medicine ^*  (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h BROWN UNIVERSITY   (United States)

ⁱ UNIVERSITY OF NEW SOUTH WALES   (Australia)

^j UNIVERSITY OF MELBOURNE   (Australia)

^k EDITH COWAN UNIVERSITY   (Australia)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

^m UNIVERSITY OF TÜBINGEN   (Germany)

ⁿ UNIVERSITY OF MUNICH   (Germany)

^o TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^p CAPITAL MEDICAL UNIVERSITY   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; APOLIPOPROTEIN E4; PITTSBURGH COMPOUND B; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; PRESENILIN 1; PRESENILIN 2; PSEN1 PROTEIN, HUMAN; PSEN2 PROTEIN, HUMAN;

ADULT; ALLELE; ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; ASYMPTOMATIC DISEASE; AUTOSOMAL DOMINANT ALZHEIMER DISEASE; AUTOSOMAL DOMINANT DISORDER; BRAIN DISEASE; BRAIN SCINTISCANNING; BRAIN STEM; CEREBRAL AMYLOIDOSIS; CLINICAL EVALUATION; COGNITIVE DEFECT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; EPISODIC MEMORY; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; LANGUAGE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; OBSERVATIONAL STUDY; POSITRON EMISSION TOMOGRAPHY; PRECUNEUS; PRIORITY JOURNAL; SYMPTOM; WORKING MEMORY; BRAIN; DISEASE COURSE; GENETICS; LONGITUDINAL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGY; SCINTISCANNING;

ADULT; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOIDOSIS; APOLIPOPROTEIN E4; BRAIN; BRAIN DISEASES; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PRESENILIN-1; PRESENILIN-2;

EID: 84951773904     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001903     Document Type: Article

References (40)

1. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-185.
2. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-128.
3. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 1992;42:631-639.
4. Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000;283:1571-1577.
5. Ingelsson M, Fukumoto H, Newell KL, et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 2004;62:925-931.
6. Price JL, McKeel DW Jr, Buckles VD, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 2009;30:1026-1036.
7. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007;130: 2837-2844.
8. Tolboom N, van der Flier WM, Yaqub M, et al. Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment. Neurology 2009;73:2079-2085.
9. Rentz DM, Locascio JJ, Becker JA, et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol 2010;67:353-364.
10. Pike KE, Ellis KA, Villemagne VL, et al. Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. Neuropsychologia 2011;49:2384-2390.
11. Kantarci K, Lowe V, Przybelski SA, et al. APOE modifies the association between Ab load and cognition in cogni-tively normal older adults. Neurology 2012;78:232-240.
12. Sperling RA, Johnson KA, Doraiswamy PM, et al; AV45-A05 Study Group. Amyloid deposition detected with flor-betapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging 2013;34:822-831.
13. Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol 2009;66:1476-1481.
14. Resnick SM, Sojkova J, Zhou Y, et al. Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology 2010;74:807-815.
15. Villemagne VL, Pike KE, Chételat G, et al. Longitudinal assessment of Ab and cognition in aging and Alzheimer disease. Ann Neurol 2011;69:181-192.
16. Ewers M, Insel P, Jagust WJ, et al; Alzheimer's Disease Neuroimaging Initiative (ADNI). CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex 2012;22:1993-2004.
17. Landau SM, Mintun MA, Joshi AD, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012;72:578-586.
18. Lim YY, Ellis KA, Pietrzak RH, et al. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology 2012;79:1645-1652.
19. Doraiswamy PM, Sperling RA, Coleman RE, et al: AV45-A11 Study Group. Amyloid-b assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 2012;79:1636-1644.
20. Lim YY, Pietrzak RH, Ellis KA, et al. Rapid decline in episodic memory in healthy older adults with high amyloid-b. J Alzheimers Dis 2013;33:675-679.
21. Ellis KA, Lim YY, Harrington K, et al. Decline in cognitive function over 18 months in healthy older adults with high amyloid-b. J Alzheimers Dis 2013;34:861-871.
22. Snitz BE, Weissfeld LA, Lopez OL, et al. Cognitive trajectories associated with b-amyloid deposition in the oldest-old without dementia. Neurology 2013;80:1378-1384.
23. Lim YY, Maruff P, Pietrzak RH, et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain 2014;137:221-231.
24. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008;65:1509-1517.
25. Marchant NL, Reed BR, DeCarli CS, et al. Cerebrovas-cular disease, b-amyloid, and cognition in aging. Neuro-biol Aging 2012;33:1006.e1025-e1036.
26. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355-1365.
27. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-292.
28. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795-804.
29. Morris JC, Aisen PS, Bateman RJ, et al. Developing an international network for Alzheimer research: The Domi-nantly Inherited Alzheimer Network. Clin Investig (Lond) 2012;2:975-984.
30. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
31. Talbot C, Lendon C, Craddock N, Shears S, Morris JC, Goate A. Protection against Alzheimer's disease with apoE epsilon 2. Lancet 1994;343:1432-1433.
32. Cruchaga C, Haller G, Chakraverty S, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One 2012;7:e31039.
33. Storandt M, Balota DA, Aschenbrenner AJ, Morris JC. Clinical and psychological characteristics of the initial cohort of the Dominantly Inherited Alzheimer Network (DIAN). Neuropsychology 2014;28:19-29.
34. Benzinger TL, Blazey T, Jack CR Jr, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proc Natl Acad Sci USA 2013;110: E4502-E4509.
35. Su Y, D'Angelo GM, Vlassenko AG, et al. Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS One 2013;8:e73377.
36. Su Y, Blazey TM, Snyder AZ, et al. Partial volume correction in quantitative amyloid imaging. Neuroimage 2015;107:55-64.
37. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-452.
38. Ryman DC, Acosta-Baena N, Aisen PS, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology 2014;83:253-260.
39. Hedden T, Oh H, Younger AP, Patel TA. Meta-analysis of amyloid-cognition relations in cognitively normal older adults. Neurology 2013;80:1341-1348.
40. Sassi C, Guerreiro R, Gibbs R, et al. Investigating the role of rare coding variability in Mendelian dementia genes (APP, PSEN1, PSEN2, GRN, MAPT, and PRNP) in late-onset Alzheimer's disease. Neurobiol Aging 2014;35: 2881.e2881-e2886.